Labcorp Holdings' Lumipulse pTau-217/Beta Amyloid 42 Ratio Launch Enhances Alzheimer's Diagnostics Capabilities, Supporting Revenue Growth

Labcorp Holdings (LH) has seen a 10% price increase in the past month following the launch of Lumipulse® pTau-217/Beta Amyloid 42 Ratio, a significant enhancement in Alzheimer's diagnostics. The company's second-quarter earnings beat and product innovations, such as Test Finder AI tool with AWS, may have supported upward momentum in its stock price. Labcorp's total shareholder return over the past five years was 83.10%, highlighting robust growth amidst evolving market conditions.